Navigation Links
First Choice ER to Donate Over $15,000 in Medical Supplies to Haitian Earthquake Victims
Date:2/3/2010

HOUSTON and DALLAS, Feb. 3 /PRNewswire/ -- First Choice Emergency Room's owner, along with the company's management, medical staff, and employees, are making multiple monetary and in-kind donations to the victims of the January 12 earthquake in Haiti.

In response to the magnitude 7.0 quake, which has left an estimated 200,000 people dead, over a million homeless, and over 195,000 awaiting medical attention, First Choice owner Jack Novak personally purchased over $15,000 in medical supplies to be palletized and shipped to the Haitian people. As of January 26, 13 hospitals had been opened in Port-au-Prince, but the devastated country is still in desperate need of health supplies and monetary aid.

In addition to the medical supplies, First Choice ER and its employees banded together to send a monetary donation. And with 80 percent of the Haitian population living below the poverty line before the earthquake, the aid is urgently needed. First Choice plans for both the supplies and the money to reach the victims as quickly as possible, so that it may be put to the best use.

"Even when your line of work is saving lives every day, nothing can prepare you for a disaster of this magnitude," said Novak. "At First Choice, responding to emergencies is what we do. We felt that it was essential to do everything within our means to respond to those in desperate need in every way we can."

About First Choice Emergency Ro
'/>"/>

SOURCE First Choice Emergency Room
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a ... of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, ... four investor conferences in September. , ... Company, LLC Emerging Growth Conference in ... , President & Chief Executive Officer, will present a ...
(Date:8/31/2015)... Israel , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the ... commercializes biomedical innovations in ophthalmology and cancer diagnostics, ... Technologies (TASE: MCTC), has identified several new genetic ... the jawbone in patients treated with bisphosphonate drugs ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
(Date:8/31/2015)... ... 31, 2015 , ... The Lisle family law firm of Momkus McCluskey, ... by his peers to earn a “Leading Lawyers” distinction. , The ... state of Illinois. The nomination process is based on statewide peer survey nominations and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about getting a hair transplant ... learning more about the procedure beyond the information found on the Internet can attend ... surgeon Parsa Mohebi will be on hand to answer patients hair transplant questions at ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Dr. Paul ... “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders ... traumatic injuries to the entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications ... that it has officially launched a new website and company identity ( diablopublications.com) ... are more closely aligned with the company’s strategic vision for growth and expansion ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... probably first had blood tests, an imaging test like an ... "Is all this really necessary?" you might have wondered. ... a growing body of evidence suggests that overuse of diagnostic ...
... ovarian cancer with the drug bevacizumab ("Avastin") delays the disease ... international clinical trial co-led by Drs. Amit Oza of the ... St James,s Institute of Oncology, Leeds, UK. The ... Medicine, report that the drug halted the cancer,s return ...
... WEDNESDAY, Dec. 28 (HealthDay News) -- Severely ill hospital patients ... and often wear compression stockings and/or take blood thinners to ... Lovenox (enoxaparin) to the mix does not reduce their ... appearing in the Dec. 29 issue of the New ...
... News) -- Disease-causing strains of the fungus Fusarium ... common source of infection in humans, according to a new ... diseases in agricultural crops, but some species of the fungus ... For example, Fusarium was the cause of ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... but old-fashioned letter-writing may have a more beneficial lasting effect ... war zones, most in Iraq, researchers found that letters from ... onto paper or typed into an email -- served as ...
... -- Regular beer and even some brands of beer labeled ... for people with celiac disease, a new study says. ... gluten called hordein. However, some beer companies contend that the ... levels, according to a release from the Journal of ...
Cached Medicine News:Health News:Is American Medicine Too Test Happy? 2Health News:Is American Medicine Too Test Happy? 3Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2Health News:Adding Lovenox Didn't Reduce Blood Clot Death Risk in Study 2Health News:Fungus Found in Sinks Can Cause Serious Infections 2Health News:In High-Tech Age, the Good Old Letter Still Holds Sway 2Health News:In High-Tech Age, the Good Old Letter Still Holds Sway 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: